Raging Bull (homepage)
Enter symbol:
Find symbol 
Advanced Viral Research (BB: ADVR)
ADVR Quote | ADVR Msg Board | ADVR LiveCharts | ADVR Chart | ADVR News | ADVR Company Info | ADVR I-Watch | ADVR Insider | ADVR Analyst Recs | ADVR Top Holders
« ADVR Message list  |  Reply to msg.  |  Post new msg.   « Older | Newer »   
By: gatorbak
11 Dec 2003, 06:52 PM EST
Msg. 130687 of 130706
Jump to msg. #  
Advanced Viral Research Corp. Announces Retention of James T. D'Olimpio, MD As 'Spokesperson at Large'

YONKERS, N.Y., Nov. 18 /PRNewswire-FirstCall/ -- Advanced Viral Research
Corp. (OTC Bulletin Board: ADVR) today announced the retention of James T.
D'Olimpio M.D., as the Company's "Spokesperson at Large." In this new role,
Dr. D'Olimpio will assist the Company in bridging the information gap between
the investment community and the medical community in areas surrounding the
further development and maturation of clinical trials of AVR118 (formerly
known as Product R). In addition to this consulting role, Dr. D'Olimpio will
continue as a member of the Company's Scientific Advisory Board.
Eli Wilner, Chairman of the Company's Board said, "Jim has assisted the
Company in the clinical development of AVR118, particularly advising us on
matters pertaining to issues related to quality of life and cachexia reversal.
Jim's new role, as a spokesman for the Company regarding the potential use of
AVR118 in the treatment of cachexia, will strengthen our ability to
communicate the findings coming from our Israeli clinical trials to the
investment community and general public. We appreciate his willingness to
accept these additional, consultative responsibilities. Jim has an extensive
history in oncology research and treatment. His research focuses primarily on
the areas of symptom control, palliative care, and cancer cachexia."
Dr. D'Olimpio is the director of Supportive Oncology and the Palliative
Care/Cancer Pain Service at North Shore University Hospital in Manhasset, New
York. He also is an Assistant Professor of Medicine at the New York
University School of Medicine. He is triple Board Certified in the fields of
Internal Medicine, Medical Oncology and Hospice/Palliative Medicine. Dr.
D'Olimpio has served on the ADVR Scientific Advisory Board since February of
"The recent preliminary clinical results reported by the Company from its
Israeli Phase I/II AIDS trial contain much encouraging raw data," Dr.
D'Olimpio said. "It is of the utmost importance to sustain the momentum by
increasing awareness of what Advanced Viral is trying to accomplish in
furthering research of its technology platform in several related disease
D'Olimpio noted that there are many similarities in Quality of Life Issues
and cachexia that are shared by patients with AIDS and cancer. "Patients
suffer from cachexia in both diseases, and in fact, many patients with AIDS
have co-existent cancers, making the situation even more complex and
As an author of multiple professional and technical papers, Dr.
D'Olimpio's findings have appeared in exclusive journals such as the Journal
of Clinical Oncology, Cancer Investigation, JAMA, American Journal of Surgery,
Journal of Palliative Medicine and the Journal of Clinical Pharmacology. He
is on the editorial staff of The Journal of Pain and Symptom Management and
Dr. D'Olimpio is a member of several professional organizations, including
the American Society of Clinical Oncology and the American Academy of Hospice
and Palliative Medicine. He is also a member of the Multi-National
Association for Supportive Care in Cancer (MASCC), where he is a member of
their select cachexia research group, and the CALGB (Cancer and Leukemia Group
B) where he sits on the symptom control committee. Dr. D'Olimpio also was the
medical director for the Hospice Care Network Westbury, New York. He has
lectured in related topics in symptom management throughout the country and in
Europe and has appeared on CNN as a national expert in pain control.
North Shore University Hospital is a major affiliate of the North Shore -
Long Island Jewish Health System, and has recently been named the "Number One
Hospital in America" by Modern Maturity Magazine, the publication of the AARP
(American Association of Retired Persons).
ADVR's AVR118 represents a biopolymer chemistry that possesses novel
immunomodulator activity. This peptide-nucleic acid, which to date has shown
no indication of human toxicity, appears to stimulate the proinflammatory
responses required to combat viral infections such as AIDS and human papilloma
virus and to dampen aberrant autoimmune-type inflammatory responses, such as
occur in patients with rheumatoid arthritis. Therefore, AVR118 has been
termed a "switch-type" immunomodulator. AVR118 is in clinical trials in
Israel for the treatment of cachexia (body wasting) in patients with AIDS.
For further information regarding Advanced Viral Research Corp., please
visit our website at http://www.adviral.com .

Advanced Viral Research Corp., based in Yonkers, New York, is a
biopharmaceutical firm dedicated to improving patients' lives by researching,
developing and bringing to market new and effective therapies for viral and
other diseases.

Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company. AVR118 (Product R)
is not approved by the U.S. Food and Drug Administration or any comparable
agencies of any other countries. There is no assurance that the Company will
be able to secure the financing necessary to continue and/or complete the
clinical trials of AVR118 or satisfy certain other conditions relating to
clinical trials including obtaining adequate insurance on terms acceptable to
the Company or that if completed, clinical trials performed outside the United
States will assist the Company in obtaining FDA or other approval. The
Company undertakes no obligation to update or revise the information contained
in this announcement whether as a result of new information, future events or
circumstances or otherwise.

Eli Wilner

SOURCE Advanced Viral Research Corp.

Web site: http://www.adviral.com

Company News On-Call: http://www.prnewswire.com/comp/903002.html

(Voluntary Disclosure: Position- Long; LT Rating- Strong Buy)

•  Try a FREE offer at Ameritrade
•  $7 Trades, No Inactivity Fee
•  Mortgage Rates are Low! Time to Refinance!
« ADVR Message list  |  Reply to msg.  |  Post new msg.   « Older | Newer »   

You can also:

My Boardmarks Help
Board New Posts
ADVR 19 new
AVXT 0 new
DMNX 0 new
ICPT 0 new
INAP 0 new
SFAD 2 new
- - - - -
Mark all msgs. read
- - - - -
Add or remove boards »

Keyboard shortcuts
Pressing these keys is the same as clicking their link equivalents. Note: Netscape users don't have to press enter after the shortcut. Mac users - use the CTRL key.
Alt 1 [Enter] First unread
Alt Z [Enter] Previous or Older
Alt X [Enter] Next or Newer

Click Here!

     » Lycos Worldwide  © Copyright 2003, Lycos, Inc. All Rights Reserved.  Lycos® is a registered trademark of Carnegie Mellon University.
     About Terra Lycos | Help | Jobs | Advertise | Business Development

     Your use of this website constitutes acceptance of the Lycos Privacy Policy and Terms & Conditions